Performance characteristics of plasma amyloid-β 40 and 42 assays

Olivia I. Okereke, Weiming Xia, Michael C. Irizarry, Xiaoyan Sun, Wei Q. Qiu, Anne M. Fagan, Pankaj D. Mehta, Bradley T. Hyman, Dennis J. Selkoe, Francine Grodstein

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Identifying biomarkers of Alzheimer's disease (AD) risk will be critical to effective AD prevention. Levels of circulating amyloid-β (Aβ) 40 and 42 may be candidate biomarkers. However, properties of plasma Aβ assays must be established. Using five different protocols, blinded samples were used to assess: intra-assay reproducibility; impact of EDTA vs. heparin anticoagulant tubes; and effect of time-to-blood processing. In addition, percent recovery of known Aβ concentrations in spiked samples was assessed. Median intra-assay coefficients of variation for the assay protocols ranged from 6-24% for Aβ40, and 8-14% for Aβ42. There were no systematic differences in reproducibility by collection method. Plasma concentrations of Aβ (particularly Aβ42) appeared stable in whole blood kept in ice packs and processed as long as 24 hours after collection. Recovery of expected concentrations was modest, ranging from -24% to 44% recovery of Aβ40, and 17% to 61% of Aβ42. In conclusion, across five protocols, plasma Aβ40 and Aβ42 levels were measured with generally low error, and measurements appeared similar in blood collected in EDTA versus heparin. While these preliminary findings suggest that measuring plasma Aβ40 and Aβ42 may be feasible in varied research settings, additional work in this area is necessary.

Original languageEnglish (US)
Pages (from-to)277-285
Number of pages9
JournalJournal of Alzheimer's Disease
Volume16
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Amyloid
Edetic Acid
Heparin
Alzheimer Disease
Biomarkers
Ice
Anticoagulants
Research

Keywords

  • Alzheimer's disease
  • Amyloid
  • Assay reliability
  • Biomarker
  • Quality control

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Okereke, O. I., Xia, W., Irizarry, M. C., Sun, X., Qiu, W. Q., Fagan, A. M., ... Grodstein, F. (2009). Performance characteristics of plasma amyloid-β 40 and 42 assays. Journal of Alzheimer's Disease, 16(2), 277-285. https://doi.org/10.3233/JAD-2009-0948

Performance characteristics of plasma amyloid-β 40 and 42 assays. / Okereke, Olivia I.; Xia, Weiming; Irizarry, Michael C.; Sun, Xiaoyan; Qiu, Wei Q.; Fagan, Anne M.; Mehta, Pankaj D.; Hyman, Bradley T.; Selkoe, Dennis J.; Grodstein, Francine.

In: Journal of Alzheimer's Disease, Vol. 16, No. 2, 2009, p. 277-285.

Research output: Contribution to journalArticle

Okereke, OI, Xia, W, Irizarry, MC, Sun, X, Qiu, WQ, Fagan, AM, Mehta, PD, Hyman, BT, Selkoe, DJ & Grodstein, F 2009, 'Performance characteristics of plasma amyloid-β 40 and 42 assays', Journal of Alzheimer's Disease, vol. 16, no. 2, pp. 277-285. https://doi.org/10.3233/JAD-2009-0948
Okereke, Olivia I. ; Xia, Weiming ; Irizarry, Michael C. ; Sun, Xiaoyan ; Qiu, Wei Q. ; Fagan, Anne M. ; Mehta, Pankaj D. ; Hyman, Bradley T. ; Selkoe, Dennis J. ; Grodstein, Francine. / Performance characteristics of plasma amyloid-β 40 and 42 assays. In: Journal of Alzheimer's Disease. 2009 ; Vol. 16, No. 2. pp. 277-285.
@article{0a8dc960f45c4a6db835d3475aa4c8f9,
title = "Performance characteristics of plasma amyloid-β 40 and 42 assays",
abstract = "Identifying biomarkers of Alzheimer's disease (AD) risk will be critical to effective AD prevention. Levels of circulating amyloid-β (Aβ) 40 and 42 may be candidate biomarkers. However, properties of plasma Aβ assays must be established. Using five different protocols, blinded samples were used to assess: intra-assay reproducibility; impact of EDTA vs. heparin anticoagulant tubes; and effect of time-to-blood processing. In addition, percent recovery of known Aβ concentrations in spiked samples was assessed. Median intra-assay coefficients of variation for the assay protocols ranged from 6-24{\%} for Aβ40, and 8-14{\%} for Aβ42. There were no systematic differences in reproducibility by collection method. Plasma concentrations of Aβ (particularly Aβ42) appeared stable in whole blood kept in ice packs and processed as long as 24 hours after collection. Recovery of expected concentrations was modest, ranging from -24{\%} to 44{\%} recovery of Aβ40, and 17{\%} to 61{\%} of Aβ42. In conclusion, across five protocols, plasma Aβ40 and Aβ42 levels were measured with generally low error, and measurements appeared similar in blood collected in EDTA versus heparin. While these preliminary findings suggest that measuring plasma Aβ40 and Aβ42 may be feasible in varied research settings, additional work in this area is necessary.",
keywords = "Alzheimer's disease, Amyloid, Assay reliability, Biomarker, Quality control",
author = "Okereke, {Olivia I.} and Weiming Xia and Irizarry, {Michael C.} and Xiaoyan Sun and Qiu, {Wei Q.} and Fagan, {Anne M.} and Mehta, {Pankaj D.} and Hyman, {Bradley T.} and Selkoe, {Dennis J.} and Francine Grodstein",
year = "2009",
doi = "10.3233/JAD-2009-0948",
language = "English (US)",
volume = "16",
pages = "277--285",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Performance characteristics of plasma amyloid-β 40 and 42 assays

AU - Okereke, Olivia I.

AU - Xia, Weiming

AU - Irizarry, Michael C.

AU - Sun, Xiaoyan

AU - Qiu, Wei Q.

AU - Fagan, Anne M.

AU - Mehta, Pankaj D.

AU - Hyman, Bradley T.

AU - Selkoe, Dennis J.

AU - Grodstein, Francine

PY - 2009

Y1 - 2009

N2 - Identifying biomarkers of Alzheimer's disease (AD) risk will be critical to effective AD prevention. Levels of circulating amyloid-β (Aβ) 40 and 42 may be candidate biomarkers. However, properties of plasma Aβ assays must be established. Using five different protocols, blinded samples were used to assess: intra-assay reproducibility; impact of EDTA vs. heparin anticoagulant tubes; and effect of time-to-blood processing. In addition, percent recovery of known Aβ concentrations in spiked samples was assessed. Median intra-assay coefficients of variation for the assay protocols ranged from 6-24% for Aβ40, and 8-14% for Aβ42. There were no systematic differences in reproducibility by collection method. Plasma concentrations of Aβ (particularly Aβ42) appeared stable in whole blood kept in ice packs and processed as long as 24 hours after collection. Recovery of expected concentrations was modest, ranging from -24% to 44% recovery of Aβ40, and 17% to 61% of Aβ42. In conclusion, across five protocols, plasma Aβ40 and Aβ42 levels were measured with generally low error, and measurements appeared similar in blood collected in EDTA versus heparin. While these preliminary findings suggest that measuring plasma Aβ40 and Aβ42 may be feasible in varied research settings, additional work in this area is necessary.

AB - Identifying biomarkers of Alzheimer's disease (AD) risk will be critical to effective AD prevention. Levels of circulating amyloid-β (Aβ) 40 and 42 may be candidate biomarkers. However, properties of plasma Aβ assays must be established. Using five different protocols, blinded samples were used to assess: intra-assay reproducibility; impact of EDTA vs. heparin anticoagulant tubes; and effect of time-to-blood processing. In addition, percent recovery of known Aβ concentrations in spiked samples was assessed. Median intra-assay coefficients of variation for the assay protocols ranged from 6-24% for Aβ40, and 8-14% for Aβ42. There were no systematic differences in reproducibility by collection method. Plasma concentrations of Aβ (particularly Aβ42) appeared stable in whole blood kept in ice packs and processed as long as 24 hours after collection. Recovery of expected concentrations was modest, ranging from -24% to 44% recovery of Aβ40, and 17% to 61% of Aβ42. In conclusion, across five protocols, plasma Aβ40 and Aβ42 levels were measured with generally low error, and measurements appeared similar in blood collected in EDTA versus heparin. While these preliminary findings suggest that measuring plasma Aβ40 and Aβ42 may be feasible in varied research settings, additional work in this area is necessary.

KW - Alzheimer's disease

KW - Amyloid

KW - Assay reliability

KW - Biomarker

KW - Quality control

UR - http://www.scopus.com/inward/record.url?scp=60349123096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60349123096&partnerID=8YFLogxK

U2 - 10.3233/JAD-2009-0948

DO - 10.3233/JAD-2009-0948

M3 - Article

C2 - 19221417

AN - SCOPUS:60349123096

VL - 16

SP - 277

EP - 285

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -